136 related articles for article (PubMed ID: 38773189)
1. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Sci Rep; 2024 May; 14(1):11570. PubMed ID: 38773189
[TBL] [Abstract][Full Text] [Related]
2. Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20).
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Res Sq; 2023 Sep; ():. PubMed ID: 37720027
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Infante JR; Korn RL; Rosen LS; LoRusso P; Dychter SS; Zhu J; Maneval DC; Jiang P; Shepard HM; Frost G; Von Hoff DD; Borad MJ; Ramanathan RK
Br J Cancer; 2018 Jan; 118(2):153-161. PubMed ID: 28949957
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
[TBL] [Abstract][Full Text] [Related]
5. Investigating the contribution of hyaluronan to the breast tumour microenvironment using multiparametric MRI and MR elastography.
Reeves EL; Li J; Zormpas-Petridis K; Boult JKR; Sullivan J; Cummings C; Blouw B; Kang D; Sinkus R; Bamber JC; Jamin Y; Robinson SP
Mol Oncol; 2023 Jun; 17(6):1076-1092. PubMed ID: 37081807
[TBL] [Abstract][Full Text] [Related]
6. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study.
Seki T; Saida Y; Kishimoto S; Lee J; Otowa Y; Yamamoto K; Chandramouli GV; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
Neoplasia; 2022 Aug; 30():100793. PubMed ID: 35523073
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.
Thompson CB; Shepard HM; O'Connor PM; Kadhim S; Jiang P; Osgood RJ; Bookbinder LH; Li X; Sugarman BJ; Connor RJ; Nadjsombati S; Frost GI
Mol Cancer Ther; 2010 Nov; 9(11):3052-64. PubMed ID: 20978165
[TBL] [Abstract][Full Text] [Related]
8. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20).
Wong KM; Horton KJ; Coveler AL; Hingorani SR; Harris WP
Curr Oncol Rep; 2017 Jul; 19(7):47. PubMed ID: 28589527
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
11. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Morosi L; Meroni M; Ubezio P; Fuso Nerini I; Minoli L; Porcu L; Panini N; Colombo M; Blouw B; Kang DW; Davoli E; Zucchetti M; D'Incalci M; Frapolli R
J Exp Clin Cancer Res; 2021 Sep; 40(1):286. PubMed ID: 34507591
[TBL] [Abstract][Full Text] [Related]
12. Impact of Arterial Input Function and Pharmacokinetic Models on DCE-MRI Biomarkers for Detection of Vascular Effect Induced by Stroma-Directed Drug in an Orthotopic Mouse Model of Pancreatic Cancer.
Cao J; Pickup S; Rosen M; Zhou R
Mol Imaging Biol; 2023 Aug; 25(4):638-647. PubMed ID: 37166575
[TBL] [Abstract][Full Text] [Related]
13. Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration.
Brundel DH; Feeney OM; Nowell CJ; Suys EJ; Gracia G; Kaminskas LM; McIntosh MM; Kang DW; Porter CJ
Nanomedicine (Lond); 2021 Feb; 16(4):275-292. PubMed ID: 33560142
[No Abstract] [Full Text] [Related]
14. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
[TBL] [Abstract][Full Text] [Related]
15. Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma.
Maloney E; DuFort CC; Provenzano PP; Farr N; Carlson MA; Vohra R; Park J; Hingorani SR; Lee D
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31167451
[TBL] [Abstract][Full Text] [Related]
16. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression.
Li X; Shepard HM; Cowell JA; Zhao C; Osgood RJ; Rosengren S; Blouw B; Garrovillo SA; Pagel MD; Whatcott CJ; Han H; Von Hoff DD; Taverna DM; LaBarre MJ; Maneval DC; Thompson CB
Clin Cancer Res; 2018 Oct; 24(19):4798-4807. PubMed ID: 30084839
[No Abstract] [Full Text] [Related]
17. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Ramanathan RK; McDonough SL; Philip PA; Hingorani SR; Lacy J; Kortmansky JS; Thumar J; Chiorean EG; Shields AF; Behl D; Mehan PT; Gaur R; Seery T; Guthrie KA; Hochster HS
J Clin Oncol; 2019 May; 37(13):1062-1069. PubMed ID: 30817250
[TBL] [Abstract][Full Text] [Related]
18. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Doherty GJ; Tempero M; Corrie PG
Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
[TBL] [Abstract][Full Text] [Related]
19. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.
Wang S; Bager CL; Karsdal MA; Chondros D; Taverna D; Willumsen N
J Transl Med; 2021 Jan; 19(1):39. PubMed ID: 33478521
[TBL] [Abstract][Full Text] [Related]
20. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]